ALNY
Price
$328.81
Change
+$0.81 (+0.25%)
Updated
Jul 25 closing price
Capitalization
42.87B
3 days until earnings call
INSM
Price
$103.95
Change
+$0.43 (+0.42%)
Updated
Jul 25 closing price
Capitalization
19.75B
10 days until earnings call
Interact to see
Advertisement

ALNY vs INSM

Header iconALNY vs INSM Comparison
Open Charts ALNY vs INSMBanner chart's image
Alnylam Pharmaceuticals
Price$328.81
Change+$0.81 (+0.25%)
Volume$666.68K
Capitalization42.87B
Insmed
Price$103.95
Change+$0.43 (+0.42%)
Volume$1.4M
Capitalization19.75B
ALNY vs INSM Comparison Chart in %
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. INSM commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Buy and INSM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ALNY: $328.81 vs. INSM: $103.95)
Brand notoriety: ALNY and INSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 76% vs. INSM: 36%
Market capitalization -- ALNY: $42.87B vs. INSM: $19.75B
ALNY [@Biotechnology] is valued at $42.87B. INSM’s [@Biotechnology] market capitalization is $19.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • INSM’s FA Score: 1 green, 4 red.
According to our system of comparison, both ALNY and INSM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 3 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).

  • ALNY’s TA Score: 3 bullish, 5 bearish.
  • INSM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, INSM is a better buy in the short-term than ALNY.

Price Growth

ALNY (@Biotechnology) experienced а +2.58% price change this week, while INSM (@Biotechnology) price change was +1.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

INSM is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($42.9B) has a higher market cap than INSM($19.7B). INSM YTD gains are higher at: 50.565 vs. ALNY (39.735). ALNY has higher annual earnings (EBITDA): -152.58M vs. INSM (-917.87M). ALNY has more cash in the bank: 2.63B vs. INSM (1.2B). INSM has less debt than ALNY: INSM (1.14B) vs ALNY (1.3B). ALNY has higher revenues than INSM: ALNY (2.35B) vs INSM (381M).
ALNYINSMALNY / INSM
Capitalization42.9B19.7B218%
EBITDA-152.58M-917.87M17%
Gain YTD39.73550.56579%
P/E RatioN/AN/A-
Revenue2.35B381M616%
Total Cash2.63B1.2B220%
Total Debt1.3B1.14B114%
FUNDAMENTALS RATINGS
ALNY vs INSM: Fundamental Ratings
ALNY
INSM
OUTLOOK RATING
1..100
247
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
2211
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4441
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INSM's Valuation (96) in the Biotechnology industry is in the same range as ALNY (99). This means that INSM’s stock grew similarly to ALNY’s over the last 12 months.

INSM's Profit vs Risk Rating (11) in the Biotechnology industry is in the same range as ALNY (22). This means that INSM’s stock grew similarly to ALNY’s over the last 12 months.

INSM's SMR Rating (100) in the Biotechnology industry is in the same range as ALNY (100). This means that INSM’s stock grew similarly to ALNY’s over the last 12 months.

INSM's Price Growth Rating (41) in the Biotechnology industry is in the same range as ALNY (44). This means that INSM’s stock grew similarly to ALNY’s over the last 12 months.

INSM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALNY (100). This means that INSM’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYINSM
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
72%
MACD
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
69%
Declines
ODDS (%)
Bearish Trend 7 days ago
65%
Bearish Trend 10 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
61%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SIXP29.780.05
+0.17%
AllianzIM US Lrg Cp 6M Bfr10 Mar/Sep ETF
PMMR25.42N/A
N/A
PGIM S&P 500 Max Buffer ETF - March
DFCA48.99-0.01
-0.01%
Dimensional California Municipal Bd ETF
FENI33.85-0.08
-0.24%
Fidelity Enhanced International ETF
BABX27.39-0.47
-1.69%
GraniteShares 2x Long BABA Daily ETF